July 29, 2021, 8:28 am
Headlines :

 Delhi AIIMS to start Covaxin trial on children from Tuesday

Social Media Share

The All India Institute of Medical Sciences (AIIMS) is learnt to possess started screening children aged 6-12 years for the clinical trials of India’s first indigenously developed Covid-19 vaccine, Bharat Biotech’s Covaxin.

Sources said that the recruitment and clinical trials of the youngsters aged 6-12 years will start from Tuesday. The trial on children aged 6-12 has already started at AIIMS Patna.

Participants would tend the vaccine after their screening report comes. The trial would ensure if the Bharat Biotech jab is suitable for youngsters .

MS Education Academy
Delhi AIIMS has decided to start out the trial drive after the recruitment and clinical test for single-dose Covaxin for 12-18 age bracket is over.

After the recruitment of 6-12 year-old children, AIIMS Delhi are going to be conducting trials for the age bracket 2-6 years of youngsters . The trials are happening at 525 centres.

The screening of youngsters for the trial of single-dose Covaxin among those aged between 2 and 18 years started at the AIIMS in New Delhi on June 7 after India’s drug regulator had granted permission for conducting the Phase 2 and three clinical trials of Covaxin within the age bracket 2 to 18 years on May 12.

 

AIIMS Patna, Mysore Medical College and Research Institute in Karnataka have also been selected to conduct clinical trials on children.

Covaxin is getting used on adults in India’s ongoing Covid-19 vaccination drive since January 16 this year. the govt last week cautioned that albeit Covid-19 has not taken a significant shape among children till now, its impact can increase among them if there’s a change in virus behaviour or epidemiology dynamics, and said preparations are being strengthened to affect any such situation.

A national expert group has been formed to review Covid-19 infections in children and approach the pandemic during a renewed thanks to strengthen the nation’s preparedness, NITI Aayog Member (Health) V.K. Paul had said at a news conference .

 

“The group has examined signs which weren’t available four-five months before.”